Table 1.

Comparison of Recommended Eradication Regimens Based on Guidelines

Guideline	First-line therapy	Salvage therapy
Maastricht VI/Florence Consensus Report (2022)10	Area of clarithromycin resistance <15%: PPI-based triple therapy for 14 days	Bismuth-containing quadruple therapy for 14 days
	Area of clarithromycin resistance ≥15%: Bismuth-containing quadruple therapy for 14 days Quadruple concomitant therapy for 14 days	Fluoroquinolone-containing quadruple or triple therapy for 14 days
		Tailored therapy based on the result of AST (third line)
Toronto Consensus (2016)13	Area of clarithromycin resistance <15%: PPI-based triple therapy for 14 days	Bismuth-containing quadruple therapy for 14 days
	Area of clarithromycin resistance ≥15%: Bismuth-containing quadruple therapy for 14 days Quadruple concomitant therapy for 14 days	Fluoroquinolone-containing triple therapy for 14 days
ACG Clinical Guideline (2016)18	Area of clarithromycin resistance <15%, and no history of clarithromycin use: PPI-based triple therapy for 14 days	Bismuth-containing quadruple therapy for 14 days
		Fluoroquinolone-containing quadruple or triple therapy for 14 days
	Area of clarithromycin resistance ≥15%, or history of clarithromycin use: Bismuth-containing quadruple therapy for 10–14 days Quadruple concomitant therapy for 10–14 days	Quadruple concomitant therapy for 10 days
		Rifabutin-containing triple therapy for 10 days
		High-dose dual therapy for 14 days
Fifth Chinese National Consensus Report (2018)19	Bismuth-containing quadruple therapy for 10–14 days	No statement
Guideline in Korea (2021)21	PPI-based triple therapy for 14 days	Bismuth-containing quadruple therapy for 10–14 days
	Quadruple sequential therapy for 10 days
	Quadruple concomitant therapy for 10 days	Fluoroquinolone-containing triple therapy for 14 days
	PPI-based triple therapy for 7 days (after clarithromycin resistance testing)
Guideline in Japan (2019)20	PPI-based triple therapy for 7 days	PPI-based triple therapy for 7 days
	Vonoprazan-based triple therapy for 7 days	Vonoprazan-based triple therapy for 7 days

PPI, proton pump inhibitor; AST, antibiotic susceptibility test.